Lung Cancer Drugs Flashcards Preview

Pulmonary Week 3 > Lung Cancer Drugs > Flashcards

Flashcards in Lung Cancer Drugs Deck (63)
Loading flashcards...
1

What drug is only approved for treatment of non-squamous NSCLCs? Why?

Bevacizumb because it is associated with a high risk of bleeding

2

Drugs that end in 'nib' are what?

tyrosine kinase inhibitors

3

How do EGF receptors work?

In the normal cell, binding of a ligand to the receptor results in dimerization and tyrosine residue trans-phosphorylation. This initial event is transduced to the nucleus where effects upon nuclear transcription can
lead to cell growth, proliferation and the avoidance of apoptotic events.

4

What the EGFR IgG monoclonals approved for treatment of SQUAMOUS NSCLC?

-Necitumumab
-Panitumumab

5

How do EGFR monoclonals work?

competitively block binding of EGF and TGF-a to EGFR, thereby inhibiting receptor autophosphorylation

6

What step in the signaling pathway do TKIs inhibit? Result?

the phosphorylation step is
inhibited and the absence of proliferative signal leads to an apoptotic response.

7

How can resistance to TKIs arise?

-Drug binding site mutation (T790M!!!),

-Compensatory phosphorylation of the tyrosine residues (ERBB3) via MET, also known as hepatocyte growth factor receptor (HGFR) which itself possesses tyrosine kinase activity, or

-By HGF assuming an independent role in the proliferative signaling process independent of ERBB3 or EGFR

8

Where do TKIs bind?

the tyrosine kinase domain of EGFR at the ATP binding site

9

What are some common drug site mutations to TKIs that make them MORE effective?

-in-frame deletions at exon 19 or point mutations in exon 21 (L858R) in NSCLC

10

What are some common drug site mutations to TKIs that make them LESS effective?

A T790M (exon 20) mutation reduces the drug activity by preventing correct orientation of drug binding on the active site.

The T790M mutation (part of ATP binding site) may
simply be an outgrowth of pre-existing clones that are inherently resistant, because such mutations can be determined in patients who have never received one of the
TKIs.

11

What happens when the EGFR is phosphorylated?

KRAS, BRAF, MEK, to ERK/MAPK that promotes proliferation, angiogenesis, survival etc in the nucleus via transcription

12

Describe the EML4-ALK oncogene mutation.

Translocations pair these two to produce constitutive tyrosine kinase activity independent of EGF which produce activation of the MEK/ERK, P13K, and JAK-STAT pathways and cell proliferation

13

What patient population commonly has a EML4-ALK mutation?

nonsmokers, light smokers, and in adenocarcinomas

14

When is VEGF released normally?

lack of O2 stimulates HIF-1 to release VEGF to stimulate angiogenesis

15

What is a large supply of VEGF important for?

solid tumor growth

16

What are some of the downsides of using VEGF inhibitors?

-reducing the distribution of concurrent chemotherapy without a blood supply

-induces accumulation /selection of more aggressive cells

17

What mutations are more common in smokers?

-Tp53 mutations
-G:C to T:A mutations
-KRAS
-STK11
-p16 and APC methylation

18

What mutations are more common in NON-smokers?

-EGFR mutations
-EML4-ALK
-HER2 mutations
-hMSH2 expression

19

What are the most common mutations in lung adenocarcinoma?

-KRAS (25%)
-EGFR (23%)
-ALK rearrangements

recommend routine testing for EGFR and ALK rearrangements in all adenocarcinomas

20

What is the most commonly used method in most EGFR studies?

DNA sequencing

21

What is the preferred method of testing for ALK rearrangements?

FISH

22

T or F. The USPSTF recommends that all heavy smokers with a 30+ pack-year history undergo routine low-dose CT scans for small (and thus very treatable) tumors

T.

23

What is the best treatment for solid tumor?

surgical resection with drugs neo- or adjuvantly

24

Does metastasis occur earlier in SCLC or NSCLC cancers?

SCLC (so chemo/radiation is usually the only option)

25

What is the standard treatment of SCLC?

Etoposide + cisplatin+ carboplatin

26

What is the standard treatment of NSCLC?

Cisplatin AND paclitaxel, docetaxel, irinotecan, gemcitabine, vinorelbine, or pemetrexed

27

What is the preferred maintenance drug for NSCLC?

Pemetrexed, a DHFR inhibitor

28

When is pemetrexed maintenance indicated?

For patients with stable or responding disease following 4 cycles of nonpemetrexed-platinum combo chemo

29

When is Bevacizumab indicated?

for patients with non-squamous histology, no brain metastases, and no hemoptysis

30

What is a common reason for toxicity of targeted cancer drugs?

they are given frequently so toxicity occurs in a cumulative fashion